
CELG
Healthcare · Drug Manufacturers - General · $77.04B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2019
EPS trend, 90 days to now · -100.0% over 90 days · 30-day revisions 8 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jan 31, 2019 | Time not confirmed | 2.32 | 2.39 | +3.0% |
| Oct 25, 2018 | Time not confirmed | 2.22 | 2.29 | +3.2% |
| Jul 26, 2018 | Time not confirmed | 2.11 | 2.16 | +2.4% |
| May 4, 2018 | Time not confirmed | 1.96 | 2.05 | +4.6% |
| Jan 25, 2018 | Time not confirmed | 1.97 | 2.00 | +1.5% |
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic…